Immunotherapy treatments that use the immune system to fight cancer, have hit the headlines this week – the BBC ran an article ‘Have we cured cancer?” in addition to articles in news outlets such as the Guardian “Immunotherapy: the big new hope for cancer treatment“.

Scancell, a portfolio company of Calculus Capital, develops novel immunotherapies for the treatment of cancer based on its Immunobody® and Moditope® platforms. The company recently announced further encouraging results from its ongoing Phase 1/2 clinical trial of SCIB1, its DNA ImmunoBody® being developed for the treatment of patients with melanoma. Click here to listen to Scancell’s joint CEO Dr Richard Goodfellow discuss the results.